4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenol | 645393-89-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenol
• 英文别名: 4-[6-methoxy-2-(4-fluorophenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl]phenol；4-[2-(4-Fluorophenyl)-6-methoxy-1-methyl-3,4-dihydroisoquinolin-1-yl]phenol
• CAS: 645393-89-1
• 化学式: C₂₃H₂₂FNO₂
• 分子量: 363.432
• InChiKey: CLPJOCHTKDXKOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenol 在 sodium hydride 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 1.75h， 生成 (E)-1-(4-(2-(1H-imidazol-4-yl)vinyl)phenyl)-2-(4-fluorophenyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-6-ol
  参考文献：
  名称：

  基于丙烯酸的四氢异喹啉作为ERα+乳腺癌的口服生物可利用的选择性雌激素受体降解剂的发现

  摘要：

  四氢异喹啉40已被确定为有效的ERα拮抗剂和选择性雌激素受体降解剂（SERD），在体内具有良好的口服生物利用度，抗肿瘤功效和SERD活性。我们概述了导致THIQ 40的THIQ支架的发现和化学优化，并展示了支架的消旋作用，临床前物种的药代动力学研究以及THIQ 40在MCF-7人乳腺癌异种移植模型中的体内功效。

  DOI：

  10.1021/acs.jmedchem.6b01468
• 作为产物：
  描述：

  4-Benzyloxyphenyl lithium 在 三氯化铝 、 N,N-二甲基苯胺 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 、 二氯甲烷 为溶剂， 反应 0.17h， 生成 4-(2-(4-fluorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenol
  参考文献：
  名称：

  Estrogen Receptor Modulators:  Identification and Structure−Activity Relationships of Potent ERα-Selective Tetrahydroisoquinoline Ligands

  摘要：

  As part of a program aimed at the development of selective estrogen receptor modulators (SERMs), tetrahydroisoquinoline derivative 27 was discovered by high throughput screening. Successive replacements of the p-F substituent of 27 by an aminoethoxy side chain and of the 1-H of the tetrahydroisoquinoline core by a 1-Me group provided analogues 19 and 20. These compounds showed potencies in a cell-based reporter gene assay (ERE assay) varying between 0.6 and 20 nM and displayed antagonist behaviors in the MCF-7 human breast adenocarcinoma cell line with IC(50)s in the range of 2-36 nM. The effect of N-phenyl substituents on the activity and pharmacokinetic properties of tetrahydroisoquinoline analogues was explored. As a result of this investigation, two potent derivatives bearing a p-F N-aryl group, 19c and 20c, were discovered as candidates suitable for further profiling. To gain insight into the ligand-receptor interaction, the X-ray crystallographic structure of the 1-H tetrahydroisoquinoline derivative (R)-18a in complex with ERalpha-ligand binding domain (LBD)(301-553)/C-->S triple mutant was solved to 2.28 Angstrom. An overlay of this X-ray crystal structure with that reported for the complex of ERalpha-LBD301-553/carboxymethylated C and raloxifene (5) shows that both compounds bind to the same cleft of the receptor and display comparable binding modes, with differences being observed in the conformation of their "D-ring" phenyl groups.

  DOI：

  10.1021/jm030086h

文献信息

• [EN] 1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR ANTAGONISTS AND DEGRADERS<br/>[FR] COMPOSÉS ET COMPOSITIONS DE 1,2,3,4-TÉTRAHYDROISOQUINOLÉINE EN TANT QU'ANTAGONISTES ET AGENTS DE DÉGRADATION SÉLECTIFS DES RÉCEPTEURS DES ŒSTROGÈNES
  申请人：NOVARTIS AG

  公开号：WO2015092634A1

  公开（公告）日：2015-06-25

  The present invention relates to compounds of formula (I) in which n, R1, R2, R3, R4and R5 are as defined in the claims; capable of being both potent antagonists and degraders of estrogen receptors. Also described is a process for the preparation of compounds of the invention, and the invention further provides pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.

  本发明涉及式(I)化合物，其中n、R1、R2、R3、R4和R5如权利要求所述；能够作为雌激素受体的强效拮抗剂和降解剂。还描述了制备本发明化合物的方法，并且本发明进一步提供了包含该化合物的药物制剂以及使用该化合物和组合物管理与异常雌激素受体活性相关疾病或失调的方法。
• Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer
  作者：Mingzhang Gao、Min Wang、Kathy D. Miller、George W. Sledge、Qi-Huang Zheng

  DOI：10.1016/j.ejmech.2008.01.001

  日期：2008.10

  receptor-based breast cancer imaging agents for diagnostic use in biomedical imaging technique positron emission tomography (PET). Tetrahydroisoquinoline derivatives are a class of selective estrogen receptor modulators (SERMs) with high binding affinity and specificity exhibiting up to 50 folds for ERalpha over ERbeta. New carbon-11 labeled tetrahydroisoquinoline derivatives, [11C]methyl 1-(2-(4-(2-(4-f

  雌激素受体（ERs）是治疗乳腺癌和开发基于受体的乳腺癌显像剂的诱人靶标，可用于生物医学成像技术正电子发射断层扫描（PET）的诊断。四氢异喹啉衍生物是一类选择性雌激素受体调节剂（SERM），具有较高的结合亲和力和特异性，相对于ERbeta，其对ERalpha的表达高达50倍。新的碳11标记的四氢异喹啉衍生物，[11C]甲基1-（2-（4-（2-（4-氟苯基）-6-羟基-1-甲基-1,2,3,4-四氢异喹啉-1-基）苯氧基）乙基）哌啶-4-羧酸酯（[11C] 10a）和[11C]甲基1-（2-（4-（2-（4-（4-氯苯基）-6-羟基-1-甲基-1,2）首先设计，合成和评估了3,4-四氢异喹啉-1-基）苯氧基）乙基）哌啶-4-羧酸酯（[11C] 10b）。使用[11C] CH3OTf通过对其相应前体进行O- [11C]甲基化来制备目标示踪剂，并通过固相萃取（SPE）纯化程序进行分离，以40-6